(NASDAQ: EWTX) Edgewise Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.48%.
Edgewise Therapeutics's earnings in 2026 is -$157,241,000.On average, 13 Wall Street analysts forecast EWTX's earnings for 2026 to be -$214,563,555, with the lowest EWTX earnings forecast at -$242,777,493, and the highest EWTX earnings forecast at -$188,975,155. On average, 12 Wall Street analysts forecast EWTX's earnings for 2027 to be -$233,926,892, with the lowest EWTX earnings forecast at -$285,315,430, and the highest EWTX earnings forecast at -$180,082,206.
In 2028, EWTX is forecast to generate -$158,019,225 in earnings, with the lowest earnings forecast at -$211,652,173 and the highest earnings forecast at -$91,152,722.